Treatments that target the renin-angiotensin-aldosterone system (RAAS) don’t improve outcomes in adult patients hospitalized with acute COVID-19. Three separate trials of different RAAS-related ...
In a recent study posted to the medRxiv* preprint server, researchers conducted an umbrella review and meta-analysis of the renin-angiotensin-aldosterone system (RAAS) inhibitors' impact on ...
Discontinuation of RAAS inhibitors is often the first approach to manage hyperkalemia. Discontinuation of renin–angiotensin-aldosterone system (RAAS) inhibitors after the first hyperkalemia episode ...
What if there were a straightforward and relatively inexpensive way to lower the incidence of heart failure (HF), renal disease, stroke, and cognitive impairment? Cardiologist Bertram Pitt, MD, said ...
The rapid outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in the pandemic of the ongoing coronavirus disease 2019 (COVID-19). To date, this pandemic has claimed ...
A meta-analysis revealed that RAAS inhibitor monotherapy in patients with primary FSGS is significantly associated with a 32% reduction in proteinuria. Renin-angiotensin-aldosterone system (RAAS) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback